Trials / Recruiting
RecruitingNCT06686576
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
A Phase Ib/III, Open-Label, Randomized Study of Neoadjuvant QL1706 Versus Standard of Care in Participants With Untreated of Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 363 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1706 | Phase Ib/Ⅲ： QL1706 will be administered |
| DRUG | CAPEOX/Capecitabine | Phase Ⅲ：CAPEOX/Capecitabine will be administered |
Timeline
- Start date
- 2024-12-12
- Primary completion
- 2030-12-01
- Completion
- 2030-12-01
- First posted
- 2024-11-13
- Last updated
- 2025-12-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06686576. Inclusion in this directory is not an endorsement.